Status:
COMPLETED
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
Lead Sponsor:
Addrenex Pharmaceuticals, Inc.
Conditions:
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.
Eligibility Criteria
Inclusion
- Mild to moderate hypertension
- Age 18-75 years, inclusive
Exclusion
- Clinically significant illnesses or abnormalities upon evaluation
- Current treatment with 3 or more antihypertensive meds
- Presence of Type I or uncontrolled Type II diabetes
- Presence of alcohol or drug abuse
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00779181
Start Date
October 1 2008
End Date
December 1 2008
Last Update
December 17 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Austin, Texas, United States, 78704
2
Austin, Texas, United States, 78759
3
San Antonio, Texas, United States, 78217